We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$9.92M
Cap. Flow %
0.69%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9 quarters
Top 10 Avg Time Held Equity + Options
4.7 quarters
Top 20 Avg Time Held Equity + Options
4.1 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.7 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Miscellaneous 20.64%
3 Consumer Staples 0.52%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ASRT icon
26
DELISTED
Assertio
ASRT
$11.7M 0.81%
10,000
-833
-8% -$911K
2015 Q4
2 quarters
EGRX icon
27
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$11.6M 0.81%
300,000
+112,785
+60% +$4.7M
2015 Q1
5 quarters
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$125B
$11.2M 0.78%
130,000
-30,000
-19% -$2.59M
2015 Q4
2 quarters
ALDX icon
29
Aldeyra Therapeutics
ALDX
$53.4M
$11M 0.77%
1,940,458
+700,000
+56% +$3.91M
2015 Q1
5 quarters
WVE icon
30
Wave Life Sciences
WVE
$611M
$10.8M 0.75%
522,595
+346,595
+197% +$5.4M
2016 Q1
1 quarter
SNDA icon
31
Sonida Senior Living
SNDA
$1.73B
$10.4M 0.72%
39,076
+2,767
+8% +$779K
2014 Q4
6 quarters
HEDJ icon
32
PUT
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.73B
$10.1M 0.7%
+400,000
New +$10.4M
2016 Q2
0 quarters
ALDR
33
DELISTED
Alder Biopharmaceuticals
ALDR
$9.99M 0.69%
400,000
+25,000
+7% +$676K
2016 Q1
1 quarter
DXCM icon
34
DexCom
DXCM
$32.1B
$9.93M 0.69%
500,696
+394,800
+373% +$6.72M
2016 Q1
1 quarter
QURE icon
35
uniQure
QURE
$1.46B
$9.89M 0.69%
1,342,093
-100,000
-7% -$1.2M
2014 Q4
6 quarters
TEVA icon
36
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$9.85M 0.68%
196,000
-65,000
-25% -$3.46M
2015 Q3
3 quarters
CRBP icon
37
Corbus Pharmaceuticals
CRBP
$95M
$9.57M 0.66%
106,667
+65,000
+156% +$5.1M
2015 Q2
4 quarters
BPMC icon
38
DELISTED
Blueprint Medicines
BPMC
$9.4M 0.65%
464,404
+60,000
+15% +$1.09M
2015 Q2
4 quarters
AGTC
39
DELISTED
Applied Genetic Technologies Corporation
AGTC
$9.31M 0.65%
658,851
+8,260
+1% +$129K
2014 Q2
8 quarters
RGNX icon
40
Regenxbio
RGNX
$477M
$8.79M 0.61%
1,099,213
+273,817
+33% +$3.04M
2015 Q3
3 quarters
NERV icon
41
Minerva Neurosciences
NERV
$127M
$8.28M 0.57%
101,317
– –
2015 Q1
5 quarters
CDTX icon
42
DELISTED
Cidara Therapeutics
CDTX
$8.17M 0.57%
39,643
+2,500
+7% +$605K
2015 Q2
4 quarters
PFNX
43
DELISTED
Pfenex Inc.
PFNX
$8.04M 0.56%
960,877
– –
2014 Q3
7 quarters
CTMX icon
44
CytomX Therapeutics
CTMX
$512M
$7.58M 0.53%
742,021
– –
2015 Q4
2 quarters
EYPT icon
45
EyePoint Inc
EYPT
$273M
$7.54M 0.52%
266,500
– –
2014 Q4
6 quarters
FPRX
46
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$7.01M 0.49%
169,439
-284,690
-63% -$12.4M
2013 Q4
10 quarters
NEPT
47
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6.88M 0.48%
4,822
– –
2013 Q2
12 quarters
AKBA icon
48
Akebia Therapeutics
AKBA
$218M
$6.68M 0.46%
893,600
+28,600
+3% +$250K
2015 Q3
3 quarters
RNAC icon
49
Cartesian Therapeutics
RNAC
$201M
$6.3M 0.44%
+15,000
New +$6.3M
2016 Q2
0 quarters
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.24M 0.43%
502,894
– –
2015 Q4
2 quarters
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.